← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-4 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV15행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
GD2 CAR modified Tri-virus specific cytotoxic t-cells (GD2 CAR modified Tri-virus specific cytotoxic t-cells)
Children's Mercy Hospital Kansas C…·GD2
1 trials
Overview
Program
GD2 CAR modified Tri-virus specific cytotoxic t-cells
Overview
Company
Children's Mercy Hospital Kansas City
Overview
Modality
CGT
Overview
Target
GD2
Overview
Indication
Neuroblastoma
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.. Purpose: The multiple mechanisms used by solid tumors to suppress tumor-specific immune responses are a major barrier to the success of adoptively transferred tumor-specific T cells. As viruses induce potent innate and adaptive immune responses, we hypothesized tha…
Toxicology
CRS
Reported
Clinical
Safety signal
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.. Purpose: The multiple mechanisms used by solid tumors to suppress tumor-specific immune responses are a major barrier to the success of adoptively transferred tumor-specific T cells. As viruses induce potent innate and adaptive immune responses, we hypothesized tha…
Clinical
Program phase
PHASE_1